All In Biotech

Drug Trial Radar · NCT05551013

Treatment of Recurrent GBM With APG-157 Via Expanded Access

Last checked: Nov 19, 2026Latest source record: Aug 9, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

No longer available

Status

No longer available

Enrollment

Not stated

Start

Not stated

Primary completion

Not stated

Sponsor

Lead sponsor
Aveta Biomics, Inc.Industry
Sponsor type
Industry
First posted
Sep 22, 2022

More drug trials from this sponsor

Design

Study type
Expanded access
Who can join
All sexes, from 18 years, up to 85 years

Summary

As written by the sponsor on the registry.

This expanded access request will evaluate APG-157, a botanical drug under development for other cancers, as potential treatment for recurrent Glioblastoma multiforme (GBM) patients.

Conditions

  • Glioblastoma
  • Glioblastoma Multiforme

Interventions

  • APG-157Drug

    APG-157 is an orally administered drug encased in a hydrogel pastille. Arms: * Ongoing Stupp protocol (will receive concurrent TMZ + APG-157) * Progression post TMZ (will receive APG-157 only) * Ongoing Optune (will receive concurrent Optune + APG-157) * Progression post Optune (will receive APG-157 only)

Primary outcomes

What the sponsor says the trial is designed to measure.

No primary outcomes listed.

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.